PRCC and neoplasm: In addition, while the DNA methylation markers in our present study were identified from tumor tissue, several reports have demonstrated that blood‐ or urine‐based DNA methylation markers could be useful for noninvasive early diagnosis or prognosis of cancers such as prostate, bladder, colorectal, lung, and breast,21, 22 highlighting a logical next step for our studies with PRCC.